Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 70

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 2
Chunk 70
---
 Moderate
    Severe
    
    34 (50.7%)
    22 (32.8%)
    3 (4.5%)
    
    73 (52.5%)
    56 (40.3%)
    2 (1.4%)
    
    107 (51.9%)
    78 (37.9%)
    5 (2.4%)
  
    Any Serious TEAE
    5 (7.5%)
    8 (5.8%)
    13 (6.3%)
  
    Any Treatment-Related Serious TEAE
    0
    2 (1.4%)
    2 (1.0%)
  
    Any TEAE Leading to Treatment Discontinuation
    2 (3.0%)
    12 (8.6%)
    14 (6.8%)
  
    Any TEAE Leading to Study Withdrawal
    2 (3.0%)
    12 (8.6%)
    14 (6.8%)
  
    Any TEAE with Fatal Outcome 
    0
    0
    0

     System
Organ Class & Preferred Term
    Placebo
    (n=67)
    XPro1595
    (n=139)
    Total
    (n=206)
  
    General disorders and administration site conditions

    Injection site reaction
    2 (3.0%)
    73 (52.5%)
    75 (36.4%)
  
    Injection site erythema
    0
    49 (35.3%)
    49 (23.8%)
  
    Fatigue
    9 (13.4%)
    17 (12.2%)
    26 (12.6%)
  
    Injection site hypersensitivity
    0
    14 (10.1%)
    14 (6.8%)
  
    Injection site pruritus
    0
    12 (8.6%)
    12 (5.8%)
  
    Infections and infestations

    Upper respiratory tract infection
    11 (16.4%)
    9 (6.5%)
    20 (9.7%)
  
    Musculoskeletal and connective tissue disorders

    Arth